Who
Christine Ring
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Nurix Therapeutics.
In numbers
- Trades disclosed
- 319
- Buys
- 0
- Sells
- 62
- Bought
- $0
- Sold
- $8.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Feb 2021
- Last trade
- 2 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 2 Oct 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K5,786 at $8.72 | filing |
| 2 Oct 2026filed 2 Oct 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $134K5,786 at $23.19 | filing |
| 2 Oct 2026filed 2 Oct 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,786 at $0.00 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K5,787 at $8.72 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K5,387 at $25.69 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K400 at $26.64 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,787 at $0.00 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,787 at $0.00 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K5,787 at $8.72 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K5,387 at $25.69 | filing |
| 2 Sep 2026filed 2 Sep 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K400 at $26.64 | filing |
| 3 Aug 2026filed 3 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K5,787 at $8.72 | filing |
| 3 Aug 2026filed 3 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $382K16,589 at $23.05 | filing |
| 3 Aug 2026filed 3 Aug 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,787 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,787 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K5,787 at $8.72 | filing |
| 3 Aug 2026filed 3 Aug 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Sold | $382K16,589 at $23.05 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,858 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | NRIX Nurix TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,572 at $0.00 | filing |
News
Nurix Therapeutics (NASDAQ:NRIX) Director Julia Gregory Sells 22,583 Shares of Company StockNRIX · dailypolitical.com · 15 Oct 2026Nurix Therapeutics Q3 2026 Earnings: Key Financials RevealedNRIX · sci-tech-today.com · 13 Oct 2026Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNRIX · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Christine Ring; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.